---
title: 'TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive
  recurrent ovarian cancer'
date: '2024-08-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39155847/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240819181131&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Ovarian cancer is a leading cause of death from gynecological cancers
  worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management.
  In first line and subsequent relapses, maintenance strategies are offered to prolong
  intervals between lines of chemotherapy. Current maintenance options involve bevacizumab
  and poly ADP-ribose polymerase inhibitors, but these lines of therapy can only be
  used once in the disease course. Patients in first or second platinum ...
disable_comments: true
---
Ovarian cancer is a leading cause of death from gynecological cancers worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management. In first line and subsequent relapses, maintenance strategies are offered to prolong intervals between lines of chemotherapy. Current maintenance options involve bevacizumab and poly ADP-ribose polymerase inhibitors, but these lines of therapy can only be used once in the disease course. Patients in first or second platinum ...